166 related articles for article (PubMed ID: 34997451)
1. Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.
Dono A; Zhu P; Holmes E; Takayasu T; Zhu JJ; Blanco AI; Hsu S; Bhattacharjee MB; Ballester LY; Kim DH; Esquenazi Y; Tandon N
J Neurooncol; 2022 Jan; 156(2):353-363. PubMed ID: 34997451
[TBL] [Abstract][Full Text] [Related]
2. Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.
Dono A; Amsbaugh M; Martir M; Smilie RH; Riascos RF; Zhu JJ; Hsu S; Kim DH; Tandon N; Ballester LY; Blanco AI; Esquenazi Y
J Neurooncol; 2021 Mar; 152(1):153-162. PubMed ID: 33492602
[TBL] [Abstract][Full Text] [Related]
3. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
[TBL] [Abstract][Full Text] [Related]
4. PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
Dono A; Mitra S; Shah M; Takayasu T; Zhu JJ; Tandon N; Patel CB; Esquenazi Y; Ballester LY
J Neurooncol; 2021 May; 153(1):153-160. PubMed ID: 33881725
[TBL] [Abstract][Full Text] [Related]
5. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
[TBL] [Abstract][Full Text] [Related]
6. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
7.
Li J; Zhang Q; Ge P; Zeng C; Lin F; Wang W; Zhao J
Dis Markers; 2020; 2020():8888085. PubMed ID: 33299501
[TBL] [Abstract][Full Text] [Related]
8. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
9. Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit.
Tully PA; Gogos AJ; Love C; Liew D; Drummond KJ; Morokoff AP
Neurosurgery; 2016 Nov; 79(5):678-689. PubMed ID: 27409404
[TBL] [Abstract][Full Text] [Related]
10. Survival and functional status after resection of recurrent glioblastoma multiforme.
Barker FG; Chang SM; Gutin PH; Malec MK; McDermott MW; Prados MD; Wilson CB
Neurosurgery; 1998 Apr; 42(4):709-20; discussion 720-3. PubMed ID: 9574634
[TBL] [Abstract][Full Text] [Related]
11. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
12. Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?
Patrizz A; Dono A; Zhu P; Tandon N; Ballester LY; Esquenazi Y
J Neurooncol; 2021 Mar; 152(1):163-172. PubMed ID: 33481149
[TBL] [Abstract][Full Text] [Related]
13. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
[TBL] [Abstract][Full Text] [Related]
15. The role of
Dono A; Ramesh AV; Wang E; Shah M; Tandon N; Ballester LY; Esquenazi Y
Neurooncol Adv; 2021; 3(1):vdab050. PubMed ID: 34131647
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract][Full Text] [Related]
17. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
Chiesa S; Mangraviti A; Martini M; Cenci T; Mazzarella C; Gaudino S; Bracci S; Martino A; Della Pepa GM; Offi M; Gessi M; Russo R; Martucci M; Beghella Bartoli F; Larocca LM; Lauretti L; Olivi A; Pallini R; Balducci M; D'Alessandris QG
Sci Rep; 2022 Sep; 12(1):16265. PubMed ID: 36171338
[TBL] [Abstract][Full Text] [Related]
18. Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.
Dalle Ore CL; Chandra A; Rick J; Lau D; Shahin M; Nguyen AT; McDermott M; Berger MS; Aghi MK
Neurosurgery; 2019 Dec; 85(6):793-800. PubMed ID: 30445646
[TBL] [Abstract][Full Text] [Related]
19. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma.
Yong RL; Wu T; Mihatov N; Shen MJ; Brown MA; Zaghloul KA; Park GE; Park JK
J Neurosurg; 2014 Oct; 121(4):802-9. PubMed ID: 25061868
[TBL] [Abstract][Full Text] [Related]
20. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
